BioMarin PharmaceuticalWBO:BMRN +3.13%76 Net Margin % is 13.77% as of Mar. 2026, which is 414% above its 10-year median of 2.68. GuruFocus rates WBO:BMRN with a GF Score™ of 76/100 and a GF Value™ of €77.07 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, BioMarin Pharmaceutical ranks better than 79.7% on this metric.
The historical rank and industry rank for BioMarin Pharmaceutical's Net Margin % or its related term are showing as below:
WBO:BMRN'
s Net Margin % Range Over the Past 10 Years
Min: -56.43 Med: 2.68 Max: 45.9
Current: 8.29
WBO:BMRN's Net Margin % is ranked better than 79.7% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs WBO:BMRN: 8.29
BioMarin Pharmaceutical (WBO:BMRN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioMarin Pharmaceutical Net Margin % Related Terms
BioMarin Pharmaceutical Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BMRN vs ARWR, MDGL, CYTK: Net Margin % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (WBO:BMRN) has a Net Margin % of 13.77% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioMarin Pharmaceutical and its competitors. This is 414% above median its historical median of 2.68. According to the industry distribution chart, BioMarin Pharmaceutical ranks #192 out of 946 companies in the Biotechnology industry, placing it in the top 20.3%.
Is BioMarin Pharmaceutical's Net Margin % too high?
BioMarin Pharmaceutical's current Net Margin % of 13.77% is 414% above median its 10-year median of 2.68. Based on the distribution chart, BioMarin Pharmaceutical ranks #192 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Net Margin % compare to ARWR and MDGL?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #192 out of 946 companies for Net Margin %. This places BioMarin Pharmaceutical in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Net Margin % is 13.77%, which is 414% above median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (WBO:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is €77.07, compared to a current price of €52.14 — trading 32.3% below its estimated fair value. The current Net Margin % is 13.77%, which is 414% above median its 10-year median of 2.68. BioMarin Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioMarin Pharmaceutical (WBO:BMRN), the current Net Margin % is 13.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (WBO:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €52.14 is trading 32.3% below its estimated GF Value™ of €77.07.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for WBO:BMRN:
Net Margin %: 13.77% (414% above median its 10-year median of 2.68)
GF Value™: €77.07 vs. price of €52.14 (32.3% below fair value)
No single metric tells the full story. See the WBO:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
76GF Score
Get the complete analysis for WBO:BMRN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BMRN has been successfully added to your 
